Company intelligence / Profile preview

Shanghai Ennovabio Pharmaceuticals

Shanghai, Shanghai, Chinaennovabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EnnovaBio has several programs in clinical development. Lead assets include ENB‑106 and ENN‑0403 for diabetic eye diseases in Phase 2 trials. Other pipeline assets are in Phase 1 or IND stage for metabolic and autoimmune/inflammatory indications. The company leverages a proprietary systems biology platform to identify novel targets and develop small molecule therapies focused on immunology and metabolic complications prevalent in China. No late-stage or commercialized products as of May 2025.

Therapeutic areas: GastroenterologyDermatologyOphthalmologyNephrology
Modalities: Small molecule drugssiRNA
Industry: Biotech

Drug pipeline

3 assets

ENB-104

Unknown

2 more assets in the full pipeline.

Partnerships

Zhangjiang Leading Venture Capital among investors/partners

Beyond the preview

Go deeper on Shanghai Ennovabio Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Ennovabio Pharmaceuticals.